08:03 AM EDT, 10/16/2025 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) Thursday said new preclinical data from its ATR inhibitor program will be presented in a poster session at next week's conference on molecular targets and cancer therapeutics in Boston, Massachusetts.

DNA damage repair (DDR) enzymes, including ataxia telangiectasia and Rad3-related protein (ATR), are crucial for maintaining stability in cells. Rakovina's presentation will highlight its ATR inhibitor program, that has been developed with Variational AI and their Enki generative AI platform.

"The data to be presented . . . reflects the continued progress of our AI-driven drug discovery pipeline and the importance of our collaboration with Variational AI," said Mads Daugaard, chief scientific officer.

"Our ATR inhibitor drug candidates show strong efficacy and blood-brain barrier permeability, a critical unmet need in current cancer therapies."